StockData
Vera Therapeutics, Inc. logo

Vera Therapeutics, Inc. (VERA) company profile

VERANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$26.97−1.13 (-4.02%)

Close on Nov 16, 2026Market cap $1.94BP/E –Yield –

About Vera Therapeutics

Pharmaceutical Preparations, SIC 2834

Vera Therapeutics, Inc. is a late-stage clinical biopharmaceutical company that focuses on developing and commercializing therapies for individuals with severe immunological conditions. The company's primary product candidate is atacicept, a fusion protein designed for at-home self-administration via subcutaneous injection to treat autoimmune kidney conditions, most notably immunoglobulin A nephropathy. In addition to atacicept, its development programs involve investigational candidates such as MAU868 and VT-109 under licensing agreements. The company operates in the biotechnology sector and aims its investigational therapies at patients suffering from serious autoimmune and kidney disorders.

The company maintains its principal executive offices in Brisbane, California. Its operations and clinical research activities are conducted within the United States, supported by external partners for clinical trials and contract manufacturing. The provided text mentions no retail locations, operational facilities outside the United States, or additional branch offices.

Summary of the business section of Vera Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Vera Therapeutics, Inc.
Headquarters
Brisbane, CA
Address
2000 Sierra Point Parkway, Suite 1200 94005
Phone
(650) 770-0077
Website
veratx.com
Employees
249, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Francisco, California

Stock & identifiers

Ticker
VERA
Exchange
Nasdaq
IPO date
May 17, 2021
Shares outstanding
72M, Jul 29, 2026
Public float
$1.30B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
23-for-2, May 7, 2021
SEC CIK
1831828
CUSIP
92337R101
ISIN
US92337R1014
FIGI
BBG00Q72WYG3
Share class FIGI
BBG00Q72WYH2
EIN
81-2744449

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Marshall FordycePRESIDENT AND CEO, Director475,774
Joseph R. YoungSVP, FINANCE, CHIEF ACCT OFFCR80,754
Nancy Lee BomanChief Regulatory Officer44,987
Jane Wright-MitchellChief Legal Officer42,403
Laurence Matthew SkeltonChief Commercial Officer64,218
Sean GrantCHIEF FINANCIAL OFFICER119,181
David Lee JohnsonChief Operating Officer45,727
William D. TurnerChief Regulatory Officer45,313
Robert BrennerChief Medical Officer50,947
Jason S. CarterChief Legal Officer49,136
Scott W. MorrisonDirector–
Michael MorrisseyDirector0
Andrew ChengDirector17,488
James R. MeyersDirector–
Kimball HallDirector0
Christy J. OligerDirector2,987
Beth C. SeidenbergDirector135,565
Patrick G. EnrightDirector3,602,475
Christopher HiteDirector–
Maha KatabiDirector5,975,429

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.99M$9.13M$2.63M$262$137
FY2024$5.65M$31.24M$5.05M$219$103
FY2023$3.43M$1.99M$1.39M$79$105

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Marshall Fordyce, M.D.
President and Chief Executive Officer
$660.00K$2.36M$3.42M$554.40K–$6.99M+24%
Sean Grant
Chief Financial Officer
$507.00K$784.94K$1.14M$283.92K$3.00K$2.72M+21%
David Johnson
Chief Operating Officer
$510.00K$784.94K$1.14M$285.60K$3.00K$2.72M–
Robert Brenner, M.D.
Chief Medical Officer
$509.00K$784.94K$1.14M$285.04K$3.00K$2.72M-39%
William Turner
Chief Regulatory Officer
$473.00K$656.55K$951.75K$264.88K–$2.35M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 17, 2021
Offer price
$11.00
Securities offered
4,350,000
Gross proceeds
$47.85M
Exchange
Nasdaq
First trading day
May 14, 2021
First-day close
$11.50+4.5%
Lock-up ends (est.)
Nov 10, 2021

“The initial public offering price is $11.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had a total of 249 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?